Group 1 - Company Huahai Pharmaceutical announced that approximately 41.15 million restricted shares will be unlocked and listed for trading on September 25, 2025, accounting for about 2.75% of the company's total share capital [1] - For the year 2024, the revenue composition of Huahai Pharmaceutical is as follows: finished drug sales account for 60.32%, raw materials and intermediates sales account for 38.19%, technical services account for 0.66%, other businesses account for 0.55%, and other industries account for 0.28% [1] - The current market capitalization of Huahai Pharmaceutical is 34.4 billion yuan [2]

Group 1 - Company announced a credit guarantee of up to 205 million yuan for its wholly-owned subsidiary Huahai Jiancheng to meet funding needs [1] - As of the announcement date, the total external guarantees provided by the company and its subsidiaries amount to approximately 3.572 billion yuan, which is 40.15% of the latest audited equity attributable to shareholders [1] - The breakdown of guarantees includes approximately 3.105 billion yuan for subsidiaries (34.89% of the latest audited equity) and 263 million yuan for associated companies (2.95% of the latest audited equity) [1] Group 2 - For the year 2024, the revenue composition of Huahai Pharmaceutical is as follows: finished drug sales account for 60.32%, raw materials and intermediates sales account for 38.19%, technical services account for 0.66%, other businesses account for 0.55%, and other industries account for 0.28% [1] - The current market capitalization of Huahai Pharmaceutical is 34 billion yuan [2]